ERAS
Price
$8.31
Change
+$0.80 (+10.65%)
Updated
Jan 14 closing price
Capitalization
2.36B
63 days until earnings call
Intraday BUY SELL Signals
GALT
Price
$3.00
Change
-$0.07 (-2.28%)
Updated
Jan 14 closing price
Capitalization
194.06M
70 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs GALT

Header iconERAS vs GALT Comparison
Open Charts ERAS vs GALTBanner chart's image
Erasca
Price$8.31
Change+$0.80 (+10.65%)
Volume$11.28M
Capitalization2.36B
Galectin Therapeutics
Price$3.00
Change-$0.07 (-2.28%)
Volume$387.85K
Capitalization194.06M
ERAS vs GALT Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
GALT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. GALT commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and GALT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ERAS: $8.31 vs. GALT: $3.00)
Brand notoriety: ERAS and GALT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 269% vs. GALT: 66%
Market capitalization -- ERAS: $2.36B vs. GALT: $194.06M
ERAS [@Biotechnology] is valued at $2.36B. GALT’s [@Biotechnology] market capitalization is $194.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileGALT’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • GALT’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than GALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 4 TA indicator(s) are bullish while GALT’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 4 bullish, 4 bearish.
  • GALT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ERAS and GALT are a good buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а +60.74% price change this week, while GALT (@Biotechnology) price change was -15.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

GALT is expected to report earnings on Mar 26, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($2.36B) has a higher market cap than GALT($194M). ERAS YTD gains are higher at: 123.387 vs. GALT (-27.885). GALT has higher annual earnings (EBITDA): -30.17M vs. ERAS (-131.32M). ERAS has more cash in the bank: 288M vs. GALT (11.5M). ERAS has less debt than GALT: ERAS (48.3M) vs GALT (122M). ERAS (0) and GALT (0) have equivalent revenues.
ERASGALTERAS / GALT
Capitalization2.36B194M1,216%
EBITDA-131.32M-30.17M435%
Gain YTD123.387-27.885-442%
P/E RatioN/AN/A-
Revenue00-
Total Cash288M11.5M2,504%
Total Debt48.3M122M40%
FUNDAMENTALS RATINGS
GALT: Fundamental Ratings
GALT
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
88
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASGALT
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
74%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
87%
Bearish Trend 7 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
76%
Aroon
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
GALT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSSUX40.200.31
+0.78%
Goldman Sachs Small Cap Value R6
ALVIX10.660.06
+0.57%
American Century Focused Lg Cap Val Inv
DNREX13.380.06
+0.45%
Dunham Real Estate Stock N
SEVSX40.890.16
+0.39%
NAA SMid Cap Value C
TWCGX56.47-0.83
-1.45%
American Century Growth Inv

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+10.73%
RVMD - ERAS
61%
Loosely correlated
+1.06%
NUVL - ERAS
48%
Loosely correlated
+6.59%
ZNTL - ERAS
47%
Loosely correlated
+0.86%
CRNX - ERAS
47%
Loosely correlated
+2.04%
OCUL - ERAS
46%
Loosely correlated
+6.14%
More

GALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, GALT has been loosely correlated with BCAB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GALT jumps, then BCAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GALT
1D Price
Change %
GALT100%
-2.28%
BCAB - GALT
35%
Loosely correlated
+9.99%
TAOX - GALT
32%
Poorly correlated
+9.19%
RNAC - GALT
32%
Poorly correlated
-0.26%
ERAS - GALT
27%
Poorly correlated
+10.73%
AVIR - GALT
27%
Poorly correlated
+0.85%
More